Timed sequential induction chemotherapy and risk‐adapted postremission therapy for acute myelogenous leukemia

Cytogenetic analysis at the time of diagnosis predicts outcome in patients with acute myelogenous leukemia (AML). For those patients with favorable risk cytogenetics, stem cell transplant can be delayed until the time of relapse. For those patients with nonfavorable cytogenetic risk profiles, stem cell transplant may be required for optimal survival benefit. We treated patients with de novo AML and age less than 60 years first with etoposide, mitoxantrone, cytarabine, and G‐CSF (EMA‐G) to induce remission. Patients in complete remission were assigned to treatment with chemotherapy alone if they had favorable risk cytogenetics defined as the identification of a core‐binding factor translocation. Patients with any other cytogenetic profile were assigned to treatment with either autologous or allogeneic stem cell transplant depending on the availability of an HLA‐matched donor. Following EMA‐G, 33 of 40 patients (83%) achieved CR. Of the 25 patients who actually were treated with postremission chemotherapy, 21 were treated with their assigned risk‐adapted therapy. Of the 33 patients in remission, 5 year relapse‐free survival (RFS) and overall survival (OS) was 46 and 38%, respectively. Our intensive and risk‐adapted, stem cell transplant approach to the treatment of patients with AML requires a better definition of risk and does not appear to substantially improve results compared with more standard approaches. Am. J. Hematol., 2008. © 2008 Wiley‐Liss, Inc.